{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.0","upperLimit":"91.8","value":"86.3"},{"groupId":"OG001","lowerLimit":"77.9","upperLimit":"91.1","value":"85.4"},{"groupId":"OG002","lowerLimit":"84.7","upperLimit":"95.5","value":"91.1"},{"groupId":"OG003","lowerLimit":"80.3","upperLimit":"92.6","value":"87.4"}]}],"title":"6 Months (n=124,123,124,127)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.8","upperLimit":"93.7","value":"88.7"},{"groupId":"OG001","lowerLimit":"78.8","upperLimit":"91.7","value":"86.2"},{"groupId":"OG002","lowerLimit":"85.7","upperLimit":"96.1","value":"91.9"},{"groupId":"OG003","lowerLimit":"82.1","upperLimit":"93.8","value":"88.9"}]}],"title":"24 Month (n=124,123,124,126)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"124"},{"groupId":"OG003","value":"127"}],"units":"Participants"}],"description":"A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets \\< 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); \\< 5% myelocytes plus metamyelocytes in PB; Basophils in PB \\< 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 100 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.\n\nAfter the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG000","title":"Dasatinib 100 mg QD"},{"description":"Participants received 140 mg QD until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG001","title":"Dasatinib 140 mg QD"},{"description":"Participants received 50 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG002","title":"Dasatinib 50 mg BID"},{"description":"Participants received 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw. After the 2-year analysis, and with Protocol Amendment 02, participants on a BID dosing schedule were allowed to switch to a QD dosing schedule.","id":"OG003","title":"Dasatinib 70 mg BID"}],"paramType":"NUMBER","populationDescription":"All randomized imatinib-resistant participants with available data were summarized.","reportingStatus":"POSTED","timeFrame":"6 months, 24 months","title":"Percent of Participants With Complete Hematologic Response (CHR) at 6 and 24 Months Follow-Up","type":"SECONDARY","unitOfMeasure":"percentage of participants"}